Teva To Pay $270M In Propofol Hepatitis Suits
Teva Pharmaceuticals Industries Ltd. will spend roughly $270 million on suits claiming the way it packaged its anesthetic Propofol caused a hepatitis C outbreak, Teva told securities regulators Friday, revealing it...To view the full article, register now.
Already a subscriber? Click here to view full article